Skip to main content

Table 5 Summary of adverse events occurring in ≥ 2 subjects

From: The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial

Adverse events:   Camicinal  
Placebo 50 mg 75 mg Total
n = 12 n = 15 n = 6 n = 33
n (%) n (%) n (%) n (%)
No. subjects with any AE 9 (75) 12 (80) 5 (83) 26 (79)
Most frequent AEs (≥2 subjects in any single group)
Gamma-glutamyltransferase increased 4 (33) 0 2 (33) 6 (18)
 Oral candidiasis 0 2 (13) 1 (17) 3 (9)
 Blood alkaline phosphatase increased 2 (17) 0 1 (17) 3 (9)
 Decubitus ulcer 1 (8) 0 2 (33.) 3 (9)
 Constipation 1 (8) 2 (13) 0 3 (9)
 Vomiting 2 (17) 1 (7) 0 3 (9)
 Diarrhea 2 (17) 0 0 2 (6)
 Liver function test abnormal 0 2 (13) 0 2 (6)
 Supraventricular tachycardia 0 2 (13) 0 2 (6)
  1. AE adverse events